Shares of medical device company DexCom (NASDAQ:DXCM)
jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both revenue and earnings.
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.21 billion, close to analysts’ estimates. Its non-GAAP profit of $0.68 per share was 4.5% above analysts’ consensus estimates.
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.21 billion, close to analysts’ estimates. Its non-GAAP profit of $0.68 per share was 4.5% above analysts’ consensus estimates.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Profitability is a key measure of business strength.
Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting bottom-line expectations for earnings per share, the healthcare giant reported a significant revenue miss that spooked investors, driven primarily by
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an adjusted earnings per share (EPS) of $1.50—narrowly edging out the $1.49 consensus estimate—the medical device giant’
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has been defined by the explosive rise of GLP-1 weight-loss drugs and the volatility of post-pandemic earnings, Abbott has successfully completed a pivot that many [...]
Shares of medical device company DexCom (NASDAQ:DXCM)
fell 2.6% in the morning session after analysts at Piper Sandler and Bernstein lowered their price targets on the stock, citing concerns over the company's growth prospects and valuation.
The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future.
A select few continue to execute at a high level, growing their market dominance and delivering strong returns.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately -
over the past six months, healthcare stocks have gained 11.5%, nearly mirrorring the S&P 500.
DexCom (DXCM) exemplifies Growth at a Reasonable Price (GARP) with strong double-digit earnings growth, solid profitability, and a valuation justified by its industry-leading position in diabetes care.
